BCI-1446

N/A

Report date: 2024/06/04 17:51:26
NME

Base Information

Drug NameBCI-1446
Drug Alias NameBCI-1446
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsPsoriasisKidney DiseasesNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBCI Pharma
China Registration ClassN/A

Develop Information

Active CompaniesBCI Pharma
Inactive CompaniesN/A
Active IndicationsPsoriasisKidney DiseasesNeuralgia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A